TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06104527

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Standard protein enteral nutrition with enteral tracer
Description: Enteral nutrition with standard (1.3 g/kg/d) protein provision, given via a nasogastric tube. An oral L-\[1-13C\]-phenylalanine tracer is given as co-intervention. Use of an enterally given tracer is necessary to determine indicator amino acid oxidation.

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Standard protein enteral nutrition with enteral tracer
Description: Enteral nutrition with standard (1.3 g/kg/d) protein provision, given via a nasogastric tube. An oral L-\[1-13C\]-phenylalanine tracer is given as co-intervention. Use of an enterally given tracer is necessary to determine indicator amino acid oxidation.

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: High protein enteral nutrition with enteral tracer
Description: Enteral nutrition with high (2.0 g/kg/d) protein provision, given via a nasogastric tube. An oral L-\[1-13C\]-phenylalanine tracer is given as co-intervention. Use of an enterally given tracer is necessary to determine indicator amino acid oxidation.

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: High protein enteral nutrition with enteral tracer
Description: Enteral nutrition with high (2.0 g/kg/d) protein provision, given via a nasogastric tube. An oral L-\[1-13C\]-phenylalanine tracer is given as co-intervention. Use of an enterally given tracer is necessary to determine indicator amino acid oxidation.
Study: NCT06221917

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face
Description: FTF group are participants who will learn simple sutures physically present with the instructor in the same room.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Live-streaming
Description: One general surgeon (FH) will teach the participants how to do simple sutures on a mannequin, starting by explaining, then doing a live-demo step-by-step of simple wound suturing. The instructor uses a GoPro Hero 8 device on her head which is connected to the internet and produced live-streaming video, which will then be watched by LS group.
Study: NCT05962749

Intervention type: OTHER
Intervention: Assessment
Description: 3 meter backward walk test (3MBWT), 10 meter walk test (10MWT), Selective Control Assessment of the Lower Extremities (SCALE), Trunk Control Measurement Scale (TCMS), Pediatric Balance Scale (PBS), Functional Independence Measure for Children (WeeFIM), Modified Ashworth Scale (MAS)
Study: NCT06529965

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: covivio
Description: Participants will receive access to the digital health intervention covivio in addition to TAU.
Study: NCT05173480

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: Exercise therapy through conventional rehabilitation training made by physiotherapists.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional rehabilitation
Description: Exercise therapy through conventional rehabilitation training made by physiotherapists.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Rehabilitation System (VRRS)
Description: Exercise therapy through a virtual reality rehabilitation system (VRRS).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Rehabilitation System (VRRS)
Description: Exercise therapy through a virtual reality rehabilitation system (VRRS) with sensors not connected.
Study: NCT04591899

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAD/CAM splints
Description: Each of the maxillary and mandibular cast will scanned alone and then both scanned together in the centric relation using FREEDOM HD scanner1.~The CAD/ CAM splint will be designed using Exocad software; the design will be the same as the conventional one. The surveying will be done by the software and the under-cuts blocked.~The splints will be printed using Dent2 3D printer and then cured using Dentcure. The CAD/CAM splints material will be hard resin from PhotoCentric 3D.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CAD/CAM splints
Description: Each of the maxillary and mandibular cast will scanned alone and then both scanned together in the centric relation using FREEDOM HD scanner1.~The CAD/ CAM splint will be designed using Exocad software; the design will be the same as the conventional one. The surveying will be done by the software and the under-cuts blocked.~The splints will be printed using Dent2 3D printer and then cured using Dentcure. The CAD/CAM splints material will be hard resin from PhotoCentric 3D.
Study: NCT05552378

Intervention type: DEVICE
Group type: OTHER
Intervention: Multi-Gyn FloraFem
Description: Vaginal gel packed in 5 single use plastic tubes.
Study: NCT05645484

Intervention type: DRUG
Intervention: 18F-PFPN
Description: 18F-PFPN (dose: 3.0-5.4 MBq/kg) will be injected intravenously prior to imaging.

Intervention type: DRUG
Intervention: 18F-FDG
Description: 18F-FDG (dose: 3.7-5.4 MBq/kg) will be injected intravenously prior to imaging.
Study: NCT05648760

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulation training
Description: Participants randomized to the simulation condition received simulation training based on a standard training of how to communicate bad news to patients

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Simulation training
Description: Participants randomized to the simulation condition received simulation training based on a standard training of how to communicate bad news to patients
Study: NCT05638776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGEND001 cell therapy
Description: Transplantation of the cell product

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Transplantation of Placebo
Study: NCT05692193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pain education
Description: Pain education was given to the experimental group for 20-30 minutes on the day of hospitalization.
Study: NCT05949372

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Giving a biological breastfeeding position
Description: The mother is half-sitting, in the most comfortable position where she can make eye contact with her baby. The baby's head is placed on the mother's chest with her legs on the mother's stomach. With this position, gravity fixes the baby's whole body to that of its mother.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Giving a football ( armpit) position
Description: The mother sits upright, leaning back, and the baby's bottom and the right or left side of the mother is supported by pillows from whichever side she will breastfeed. The baby's head is placed on the breast that is breastfed and the feet are laid flat so that they pass under the armpit of the breastfed side. While the mother's hand on the breastfeeding side holds the baby's head, the other hand directs the breast towards the baby and breastfeeding is initiated.
Study: NCT06487026

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ArcBlate Focused Ultrasound Ablation System
Description: MR-guided High Intensity Focused Ultrasound (MRgHIFU)
Study: NCT05372003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: dupilumab injections will be prescribed and managed by dermatology as standard of care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Photo therapy
Description: light therapy will be prescribed and managed by dermatology as standard of care
Study: NCT06268925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: number of exercises will be guided to do through zoom
Study: NCT06454292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oliceridine Fumarate
Description: After subjects were enrolled, the original sedative and analgesic drugs were discontinued, and a starting dose of 6ug/kg/h of oliceridine fumarate was continuously pumped, and the time of oliceridine fumarate initiation was recorded as T0. Subjects were assessed for sedation using the RASS score, and for analgesia using the CPOT score. Waiting for the original sedative-analgesic drug to elute until CPOT ≥ 3 and RASS \> 0. Adjust the infusion rate of oliceridine fumarate according to the CPOT score (recommended to be adjusted by 2ug/kg/h, the range of adjustment is 2-20 ug /kg/h, and the maximum infusion rate is not more than 20 ug /kg/h) until the analgesic score of the subject is CPOT\<3. The interval between two trial drug rate adjustments should be ≧5 min, and a CPOT score should be performed before each drug adjustment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: After subjects were enrolled, the original sedative and analgesic drugs were discontinued, and remifentanil was continuously pumped at a starting dose of 1.5ug/kg/h. The time of remifentanil initiation was recorded as T0. Subjects were assessed for sedation using the RASS score and analgesia using the CPOT score. We waited for the original sedative-analgesic drugs to elute until CPOT ≥ 3 and RASS \> 0. The infusion rate of remifentanil was adjusted according to the CPOT score (1.5ug/kg/h is recommended, the range of adjustment is 1.5\~12μg/kg/h, and the maximum infusion rate is not more than 12μg/kg/h) until the subject's analgesic score of CPOT\<3, and the interval between the two experimental rate adjustments of the drug should be ≧5min, and the CPOT score should be performed before each adjustment of the drug. The CPOT score should be performed before each drug adjustment.
Study: NCT06376890

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red chili peppers
Description: 2.4 grams/day of powdered red chili pepper

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green Chili Pepper
Description: 2.4 grams/day of powdered green chili peppers

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2.4 grams of a metabolically equivalent placebo
Study: NCT04940390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine
Description: Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for STS101
Study: NCT05415215

Intervention type: DRUG
Group type: OTHER
Intervention: Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)
Description: PH FDC SC is administered subcutaneously (SC) as a fixed non-weight-based dose. A loading dose of 1200 milligram (mg) pertuzumab, 600 mg trastuzumab, and 30,000 units of recombinant human PH20 hyaluronidase (rHuPH20) is given in the first cycle (1 cycle is 21 days). In subsequent cycles, maintenance doses of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units rHuPH20 are administered once every 3 weeks (Q3W).
Study: NCT05458102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesatolimod
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesatolimod
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: Administered orally
Study: NCT06409351

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention group
Description: Please refer to arm descriptions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Please refer to arm descriptions
Study: NCT05458102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Description: Administered orally
Study: NCT05415215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)
Description: PH FDC SC is administered subcutaneously (SC) as a fixed non-weight-based dose. A loading dose of 1200 milligram (mg) pertuzumab, 600 mg trastuzumab, and 30,000 units of recombinant human PH20 hyaluronidase (rHuPH20) is given in the first cycle (1 cycle is 21 days). In subsequent cycles, maintenance doses of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units rHuPH20 are administered once every 3 weeks (Q3W).
Study: NCT05428436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550 ICF
Description: BI 1015550 intended Commercial Formulation (iCF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550 ICF
Description: BI 1015550 intended Commercial Formulation (iCF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550 ICF
Description: BI 1015550 intended Commercial Formulation (iCF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550 TF2
Description: BI 1015550 trial formulation 2 (TF2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550 TF2
Description: BI 1015550 trial formulation 2 (TF2)
Study: NCT05428436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550 TF2
Description: BI 1015550 trial formulation 2 (TF2)
Study: NCT06639360

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation Active
Description: The patients will be treated with cTBS and usual medical treatment after endovascular treatment
Study: NCT05415215

Intervention type: DRUG
Group type: OTHER
Intervention: Pertuzumab IV
Description: Pertuzumab is given as a fixed dose of 840 mg intravenous (IV) loading dose and then 420 mg IV for subsequent maintenance doses once every 3 weeks.
Study: NCT06639360

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation Sham
Description: The patients will be treated with sham-cTBS and usual medical treatment after endovascular treatment
Study: NCT05721222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO1160
Description: Intravenous infusion of PRO1160
Study: NCT05415215

Intervention type: DRUG
Group type: OTHER
Intervention: Trastuzumab IV
Description: Trastuzumab is given as an 8 milligram per kilogram (mg/kg) intravenous (IV) loading dose and then 6 mg/kg IV for subsequent maintenance doses once every 3 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Trastuzumab Emtansine
Description: Trastuzumab emtansine will be given at a dose of 3.6 mg/kg by intravenous (IV) infusion, once every 3 weeks.
Study: NCT06639321

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Ventricular Assist System
Description: Percutaneous Ventricular Assist System provides intraoperative circulatory support during high-risk PCI.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: extracorporeal membrane oxygenation (ECMO)
Description: ECMO provides intraoperative circulatory support during high-risk PCI.
Study: NCT06640010

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT06637982

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ridge splitting with the use of allograft and pericardium membrane
Description: ridge splitting with the use of allograft and pericardium membrane

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ridge splitting with the use of extended platelet rich fibrin
Description: ridge splitting with the use of extended platelet rich fibrin
Study: NCT06641648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NK cell
Description: Drug: Donor NK cells injection is a non-genetically modified natural killer cells therapy derived from a healthy donor.
Study: NCT06640517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netakimab
Description: netakimab will be administered subcutaneously with induction once a week for the first three weeks, then once every 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo will be administered subcutaneously at a scheme masking netakimab treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: adalimumab will be administered subcutaneously at weeks 1, 2, and then once every 2 weeks
Study: NCT06640049

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered.
Study: NCT06637956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG)
Description: Received 1 mg of nitroglycerin intranasally two minutes prior to laryngoscopy and intubation
Study: NCT05422924

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based platform. (My Viva Plan)
Description: Participants will use a web-based platform (i.e. My Viva Plan®) to improve physical function, nutrition and mindfulness.
Study: NCT05724550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: * Sugammadex(100mg/mL), 2mg/kg~* After confirming Train-of-four counts 4, patients allocated to sugammadex group receive sugammadex 2mg/kg for reversal of rocuronium at the end of the surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: * Neostigmine methylsulfate(0.5mg/mL) 0.02mg/kg~* After confirming Train-of-four counts 4, patients allocated to neostigmine group receive neostigmine 0.02mg/kg (maximum 5mg) combined with atropine 0.02mg/kg for reversal of rocuronium at the end of the surgery.
Study: NCT06038981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of 1g tranexamic acid intravenous bolus, after anesthesia was introduced
Description: The systemic use of tranexamic acid (TXA) has been shown to be effective in many types of surgery, reducing the incidence of post-operative bleeding and thereby reducing the rate of reoperation.~To evaluate if TXA systemic administration reduces postoperative blood loss in bariatric surgeries (sleeve gastrectomy operation)
Study: NCT06198127

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combination of core stability exercises and kinesio-taping
Description: the patient in the experimental group will receive the core stability exercises with kinesiology taping on trunk stabilizer muscles. the time of intervention was 30 minutes per day. The exercises such as Abdominal draw-in with a double knee to chest, Trunk twist while sitting on a medicine ball, Lying in a supine position on bed and rotating the trunk from side-to-side, Bridging exercises, the I-shaped elastic KT will apply to the four trunk muscles from their insertion to their origin: Kinesio-taping is used on global muscles such as Rectus abdominis, External obliques, Erector spinae, Quadratus lumborum. Kinesio-taping will 1 inch wide and apply on muscles for 1 to 2 days then remove for 24 hours then again apply a new one. The tension will be 10 to 15% and tape will apply on muscles which will be stretched by maintaining a posture.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core stability exercises
Description: After the baseline assessment, the patient in the control group will receive the core stability exercises with kinesio-taping on trunk stabilizer muscles. Time of rehabilitation will be 30 minutes per subject and four days per week. In first few minutes, the subject will be explained her/his task Subject will execute the exercises such as Abdominal draw-in with a double knee to chest 10- 15 times. Trunk twist while sitting on a medicine ball 10- 15 times. Lying in a supine position on bed and rotating the trunk from side-to-side 10- 15 times. Lying in a supine position on a mat and pulling upper and lower limbs upward 10- 15 times. Bridging exercises 10- 15 times, Deep Breathing and Wheelbarrow.
Study: NCT06644846

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Spatially fractionated radiation therapy
Description: Spatially fractionated radiation therapy (SFRT) enables delivery of high-dose radiation to discrete sub-volumes inside a tumour target while restricting the remainder of the target to a safer lower dose. This technique results in generation of intentionally heterogeneous dose distribution with spatial areas of hot and cold spots within the tumour, thereby sparing nearby organs at risk.
Study: NCT06644144

Intervention type: OTHER
Intervention: No Interventions
Description: No intervention so not applicable.
Study: NCT05336123

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hatha Yoga
Description: Weekly hatha yoga classes lasting 10 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Weekly health education classes lasting 10 weeks.
Study: NCT05777057

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagnodent
Description: using DIAGNDENT depends on the principle that when 655nm wavelength of Diode laser is irradiated on dental surface, intraoral bacteria metabolites will absorb it and then metabolites emit a red fluorescence. The dental surface will reflect this fluorescence and gives number between 0 and 99 on the screen of the DIAGNdent.
Study: NCT05341544

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parasym device
Description: The study will utilize the Parasym device (Parasym Health, London, United Kingdom) paired with compatible electrodes to administer the transcutaneous LLTS.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: Sham device
Study: NCT03994471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XyloCore Low Strenght, XyloCore Medium Strenght, XyloCore High Strenght
Description: XyloCore Low Strenght: 0.7% Xylitol, 0.5% Glucose, and 0.02% L-carnitine - or - XyloCore Medium Strenght: 1.5% Xylitol, 0.5% Glucose, and 0.02% L-carnitine - or - XyloCore High Strenght: 2.0% Xylitol, 1.5% Glucose, and 0.02% L-carnitine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.36%, 1.5%, 2.27%, 2.5%, 3.86%, 2.25% Glucose PD Solution
Description: Physioneal 35 or 40 (including Clear-Flex bag), Fixioneal 35 or 40, Dianeal or Dianeal Low Calcium have 1.36%, 2.27% or 3.86% glucose; Balance, Bicavera, Bicanova or Equibalance have 1.25%, 2.3%, 4.5% glucose.
Study: NCT05594810

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU + Addiction focussed - eye movement desensitization and reprocessing (AF-EMDR)
Description: A total of six 45-90 min. sessions of AF-EMDR therapy with an average frequency of twice per week added to a SCP embedded in CRA. AF-EMD therapy consists of a rationale, installating a treatment goal, desensitasing mental video's, installation of positive cognition, future template and positive ending.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU only: Community Reinforcement Approach (CRA) + SCP
Description: CRA is a comprehensive cognitive behavioural treatment that focuses on helping people discover and adopt a pleasurable, social and healthy lifestyle that is more rewarding than a lifestyle including substance use.~Within CRA a regular smoking cessation program is embedded.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU only: Community Reinforcement Approach (CRA) + SCP
Description: CRA is a comprehensive cognitive behavioural treatment that focuses on helping people discover and adopt a pleasurable, social and healthy lifestyle that is more rewarding than a lifestyle including substance use.~Within CRA a regular smoking cessation program is embedded.